+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079387
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global psoriasis biologics market is undergoing rapid transformation, driven by innovative therapies and changing regulatory dynamics. Senior leaders in pharma and healthcare now face an environment where precision medicine, supply chain adaptability, and stakeholder alignment are essential for maintaining market advantage.

Psoriasis Biologics Market Snapshot

The therapeutic landscape for psoriasis has experienced a paradigm shift as biologic medications have achieved prominent roles, offering targeted mechanisms of action for chronic disease management. With new product entries and advancements in delivery technology, both patient outcomes and market accessibility have improved. Current market strategies focus on optimizing drug efficacy, integrating patient-centric administration routes, and fortifying supply chains to meet evolving regulatory and reimbursement demands.

Scope & Segmentation of the Psoriasis Biologics Market

This comprehensive report thoroughly examines the psoriasis biologics market across all key dimensions, including product classes, distribution models, and major global regions. Stakeholders will find a structured overview of market segmentation critical for strategic planning.

  • Drug Class: Interleukin 12/23 inhibitors (e.g., ustekinumab), interleukin 17 inhibitors (e.g., brodalumab, ixekizumab, secukinumab), interleukin 23 inhibitors (e.g., guselkumab, risankizumab, tildrakizumab), tumor necrosis factor alpha inhibitors (e.g., adalimumab, etanercept, infliximab)
  • Route of Administration: Intravenous infusion and subcutaneous injection, balancing precision in clinical settings and patient-directed convenience
  • Distribution Channel: Hospital pharmacies, retail pharmacies, and specialty pharmacies, each impacting reach and support models
  • Patient Age Group: Adult patients and pediatric patients, enabling analysis of established demand and emerging growth segments
  • Geographic Regions: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East, & Africa (spanning the United Kingdom, Germany, France, Russia, Italy, Spain, UAE, and others), and Asia-Pacific (notably China, India, Japan, Australia, South Korea, among others)
  • Key Companies: Major market participants such as AbbVie Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., UCB S.A., Merck KGaA, Boehringer Ingelheim International GmbH, Celltrion, Inc., and Samsung Bioepis Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • The rise of precision-driven biologic therapies is reshaping clinical protocols, accelerating the shift away from traditional systemic treatments.
  • Rapid adoption of interleukin inhibitors is enabling more personalized patient management, with drug selection increasingly informed by comorbidities and response patterns.
  • Advancements in drug formulation and patient-friendly delivery, notably the expansion of subcutaneous options, are enhancing treatment adherence and reducing healthcare facility burdens.
  • Fragmentation in the biologics landscape is enabling niche positioning, with emerging molecules differentiated by onset speed, durability, and safety in specific populations.
  • Pediatric patient focus is generating new growth opportunities as research, labeling expansion, and access initiatives gain momentum.
  • Diversification of distribution channels and partnerships with regional distributors contribute to market resilience against trade and regulatory shifts.

Tariff Impact on Psoriasis Biologics Supply Chains

The 2025 U.S. tariffs on select biologic imports are fundamentally altering global sourcing strategies and cost structures. Manufacturers are reevaluating supplier relationships, increasing localization, and adjusting freight and inventory logistics, driving shifts in list pricing and contract terms. Some stakeholders are absorbing cost pressures to maintain market position, while others introduce new pricing models. Diversified channel strategies have proven effective in mitigating supply disruptions amid evolving regulatory guidance.

Methodology & Data Sources

This report leverages a robust, mixed-method approach combining secondary research from peer-reviewed journals, regulatory submissions, and proprietary databases with primary insights from industry leaders, market access experts, and supply chain executives. Quantitative validation uses prescription and shipment data, while expert panel reviews ensure interpretations are accurate and actionable. This comprehensive dataset supports confident decision-making.

Why This Report Matters

  • Provides actionable strategies to navigate changing biologics regulations and emerging competition.
  • Pinpoints innovation, regional shifts, and new patient segments shaping future biologic success.
  • Supports robust commercial planning, enabling senior leaders to pre-empt risks and capitalize on evolving opportunities.

Conclusion

The psoriasis biologics market is defined by targeted innovation, growing segmentation, and complex regional and regulatory pressures. Informed, agile strategies will be the hallmark of successful market participants as demand and competitive intensity continue to evolve.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologic Medications for Psoriasis Market, by Drug Class
8.1. Introduction
8.2. Interleukin 12/23 Inhibitors
8.2.1. Ustekinumab
8.3. Interleukin 17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. Interleukin 23 Inhibitors
8.4.1. Guselkumab
8.4.2. Risankizumab
8.4.3. Tildrakizumab
8.5. Tumor Necrosis Factor Alpha Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. Biologic Medications for Psoriasis Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Biologic Medications for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Pharmacies
11. Biologic Medications for Psoriasis Market, by Patient Age Group
11.1. Introduction
11.2. Adult Patients
11.3. Pediatric Patients
12. Americas Biologic Medications for Psoriasis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biologic Medications for Psoriasis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biologic Medications for Psoriasis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Novartis AG
15.3.3. Eli Lilly and Company
15.3.4. Johnson & Johnson
15.3.5. Amgen Inc.
15.3.6. UCB S.A.
15.3.7. Merck KGaA
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Celltrion, Inc.
15.3.10. Samsung Bioepis Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. CHINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. CHINA BIOLOGIC M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biologic Medications for Psoriasis market report include:
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen Inc.
  • UCB S.A.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.

Related Topics

Related Reports

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030 - Product Image

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030 - Product Image

Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Psoriasis Treatment - Global Strategic Business Report - Product Image

Psoriasis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Chronic Plaque Psoriasis Market Report 2025 - Product Image

Chronic Plaque Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.